Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations

References

• Ohayon MM, O’Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16:283–295.
   PubMed Web of Science ®Google Scholar
• National Institute of Neurological Disorders and Stroke. Restless legs syndrome fact sheet (NIH Publication No. 10-4847). Bethesda, MD: NINDS/NIH; 2010. Available from: http://www.ninds.nih.gov/disorders/restless_legs/detail_restless_legs.htm
   Google Scholar
• Hornyak M, Sohr M, Busse M. Evaluation of painful sensory symptoms in restless legs the general adult population in two Scandinavian countries. Sleep Med. 2011;12:186–189.
   PubMed Web of Science ®Google Scholar
• Hening W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 2004;5:237–246.
   PubMed Web of Science ®Google Scholar
• Sevim S, Dogu O, Kaleagasi H, et al. Correlation of anxiety and depression symptoms in patients with restless legs syndrome: a population based survey. J Neurosurg Psychiatry. 2004;75:226–230.
   PubMed Web of Science ®Google Scholar
• Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther. 2004;26:925–935.
   PubMed Web of Science ®Google Scholar
• Batool-Anwar S, Li Y, De Vito K, et al. Lifestyle factors and risk of restless legs syndrome: prospective cohort study. J Clin Sleep Med. 2016;12:187–194.
   PubMed Web of Science ®Google Scholar
• Koo BB, Bagai K, Walters AS. Restless legs syndrome: current concepts about disease pathophysiology. Tremor Other Hyperkinet Mov (NY). 2016;2:401.
   Google Scholar
• Yang Q, Li L, Chen Q, et al. Association studies of variants in MEIS1, BTBD9, and MAP2K5/SKOR1 with restless legs syndrome in a US population. Sleep Med. 2011;12:800–804.
   PubMed Web of Science ®Google Scholar
• Moore H 4th, Winkelmann J, Lin L, et al. Periodic leg movements during sleep are associated with polymorphisms in BTBD9, TOX3/BC034767, MEIS1, MAP2K5/SKOR1, and PTPRD. Sleep. 2014;37:1535–1542.
   PubMed Web of Science ®Google Scholar
• Kryger MH, Otake K, Foerster J. Low body stores of iron and restless legs syndrome: a correctable cause of insomnia in adolescents and teenagers. Sleep Med. 2002;3:127–132.
   PubMed Web of Science ®Google Scholar
• Li X, Allen RP, Earley CJ, et al. Brain iron deficiency in idiopathic restless legs syndrome measured by quantitative magnetic susceptibility at 7 tesla. Sleep Med. 2016;22:75–82.
   PubMed Web of Science ®Google Scholar
• Connor JR, Wang X, Allen RP. Altered dopaminergic profile in the putamen and substantia nigra in restless legs syndrome. Brain. 132:2403–2412.
   PubMed Web of Science ®Google Scholar
• Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19:205–213.
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1–11.
   PubMed Web of Science ®Google Scholar
• Silver N, Allen RP, Senerth J, et al. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011;12:440–444.
   PubMed Web of Science ®Google Scholar
• Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med. 2012;13:1280–1285.
   PubMed Web of Science ®Google Scholar
• García‐Borreguero D, Högl B, Ferini‐Strambi L, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis‐Ekbom Disease): results from a prospective, multicenter study over 66 weeks. Mov Disord. 2012;27:277–283.
   PubMed Web of Science ®Google Scholar
• Bogan RK, Evidente VGH, Geyer J, et al. Health care providers’ views and practices related to augmentation in restless legs syndrome: results from an electronic survey. Poster session presented at: SLEEP; 2016 Jun 11–15; Boston, Massachusetts.
   Google Scholar
• Kurlan R, Richard IH, Deeley C. Medication tolerance and augmentation in restless legs syndrome: the need for drug class rotation. Journal Gen Intern Med. 2006;21:C1–C4.
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Williams AM. Dopaminergic augmentation of restless legs syndrome. Sleep Med Rev. 2010;14:339–346.
   PubMed Web of Science ®Google Scholar
• Benes H, Garcia-Borreguero D, Ferini-Strambi L, et al. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med. 2012;13:589–597.
   PubMed Web of Science ®Google Scholar
• Allen RP, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep. 2004;27:907–914.
   PubMed Web of Science ®Google Scholar
• Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014;370:621–631.
   PubMed Web of Science ®Google Scholar
• Silber MH, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep. 2003;26:819–821.
   PubMed Web of Science ®Google Scholar
• Högl B, Garcia-Borreguero D, Trenkwalder C, et al. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med. 2011;12:351–360.
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14:675–684.
   PubMed Web of Science ®Google Scholar
• Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101–119.
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a world association of sleep medicine international restless legs syndrome study group consensus conference at the max planck institute. Sleep Med. 2007;8:520–530.
   PubMed Web of Science ®Google Scholar
• Allen RP, Ondo WG, Ball E, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med. 2011;12:431–439.
   PubMed Web of Science ®Google Scholar
• Ondo W, Romanyshyn J, Vuong KD, et al. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol. 2004;61:1393–1397.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Hogl B, Benes H, et al. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med. 2008;9:572–574.
   PubMed Web of Science ®Google Scholar
• Frauscher B, Gschliesser V, Brandauer E, et al. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels. Sleep Med. 2009;10:611–615.
   PubMed Web of Science ®Google Scholar
• Jellen LC, Lu L, Wan X, et al. Iron deficiency alters expression of dopamine-related genes in the ventral midbrain in mice. Neuroscience. 2013;252:13–23.
   PubMed Web of Science ®Google Scholar
• Hare D, Ayton S, Bush A, et al. A delicate balance: iron metabolism and diseases of the brain. Front Aging Neurosci. 2013;5:34.
   PubMed Web of Science ®Google Scholar
• Matak P, Matak A, Moustafa S, et al. Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice. Pnas. 2016;113:3428–3435.
   PubMed Web of Science ®Google Scholar
• Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults—an update for 2012: practice parameters with an evidence based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012;35:1039–1062.
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2016;87:2585–2593.
   PubMed Web of Science ®Google Scholar
• Chesson AL Jr, Wise M, Davila D, et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of practice committee of the American Academy of Sleep Medicine. Sleep. 1999;22:961–968.
   PubMed Web of Science ®Google Scholar
• Littner MR, Kushida C, Anderson WM, et al. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep. 2004;27:557–559.
   PubMed Web of Science ®Google Scholar
• Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med. 1989;320:1661–1666.
   PubMed Web of Science ®Google Scholar
• Appleby L. Rapid development of hyponatraemia during low-dose carbamazepine therapy. J Neurol Neurosurg Psychiatry. 1984;47:1138.
   PubMed Web of Science ®Google Scholar
• Tegretol® US Prescribing Information. Novartis Pharmaceuticals. East Hanover, NJ. 2014. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/tegretol.pdf
   Google Scholar
• Trenkwalder C, Beneš H, Grote L, et al. Prolonged release oxycodone–naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12:1141–1150.
   PubMed Web of Science ®Google Scholar
• FDA announces voluntary withdrawal of Pergolide products. United States Food and Drug Administration. Washington, DC: FDA. News Release; 2007. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108877.htm
   Google Scholar
• NEUPRO® Prescribing Information 2016, UBC, Inc., Smyrna, GA. Available from: https://www.neupro.com/neupro-prescribing-information.pdf?v=1489766618.
   Google Scholar
• MIRAPEX® Prescribing Information 2016, Boehringer Ingelheim Pharmaceuticals, Inc. Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Mirapex/Mirapex.pdf.
   Google Scholar
• REQUIP® Prescribing Information and Medications Guides 2016, GlaxoSmithKline, NC, USA. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Requip/pdf/REQUIP-PI-PIL.PDF.
   Google Scholar
• Voon V, Schoerling A, Wenzel S, et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol. 2011;11:1.
   PubMed Web of Science ®Google Scholar
• Serafini A, Lorenzut S, Gigli GL, et al. The use of rotigotine in the treatment of restless legs syndrome. Ther Adv Nuerol Disord. 2010;3:241–248.
   PubMedGoogle Scholar
• Silber MH, Becker PM, Earley C, et al. Medical advisory board of the Willis-Ekbom Disease Foundation. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013;88:977–986.
   PubMed Web of Science ®Google Scholar
• HORIZANT® Prescribing Information and Medications Guides 2013, Arbor Pharmaceuticals, LLC, Atlanta, GA. Available from: http://www.horizant.com.
   Google Scholar
• Kushida CA, Becker PM, Ellenbogen AL, et al. XP052 Study Group. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology. 2009;72:439–446.
   PubMed Web of Science ®Google Scholar
• Lee DO, Ziman RB, Perkins AT, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7:282–292.
   PubMed Web of Science ®Google Scholar
• Lal R, Ellenbogen A, Chen D, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol. 2012;35:165–173.
   PubMed Web of Science ®Google Scholar
• LYRICA® Prescribing Information 2016, Pfizer, Inc., New York, NY. Available from: http://www.pfizer.com
   Google Scholar
• NEURONTIN® Prescribing Information 2017, Pfizer, Inc., New York, NY. Available from: http://www.pfizer.com
   Google Scholar
• Ferrini-Strambi L, Marelli S. Pharmacotherapy for restless legs syndrome. Expert Opin Pharmacother. 2014;1127–1138.
   PubMed Web of Science ®Google Scholar
• Ferri R, Manconi M, Arico D, et al. Acute dopamine-agonist treatment in restless legs syndrome: effects on sleep architecture and NREM sleep instability. Sleep. 2010;33:793–800.
   PubMed Web of Science ®Google Scholar
• Nirenberg MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging. 2013;30:587–592.
   PubMed Web of Science ®Google Scholar
• Pondal M, Marras C, Miyasaki J, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry. 2013;84:130–135.
   PubMed Web of Science ®Google Scholar
• Manconi M, Govoni V, De Vito A, et al. Restless legs syndrome and pregnancy. Neurology. 2004;63:1065e9.
   Web of Science ®Google Scholar
• Hubner A, Krafft A, Gadient S, et al. Characteristics and determinants of restless legs syndrome in pregnancy: a prospective study. Neurology. 2013;80:738e42.
   Web of Science ®Google Scholar
• Neau JP, Porcheron A, Mathis S, et al. Restless legs syndrome and pregnancy: a questionnaire study in the Poitiers District, France. Eur Neurol. 2010;64:268e74.
   Web of Science ®Google Scholar
• Picchietti DL, Hensley JG, Bainbridge JL, et al. International Restless Legs Syndrome Study Group (IRLSSG). Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. Sleep Med Rev. 2015;22:64–77.
   PubMed Web of Science ®Google Scholar
• Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria – history, rationale, description, and significance. Sleep Med. 2014;15:860–873.
   PubMed Web of Science ®Google Scholar
• Schneider J, Krafft A, Manconi M, et al. Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome. Sleep Med. 2015;16:1342–1347.
   PubMed Web of Science ®Google Scholar
• Vadasz D, Ries V, Oertel WH. Intravenous iron sucrose for restless legs syndrome in pregnant women with low serum ferritin. Sleep Med. 2013;14:1214–1216.
   PubMed Web of Science ®Google Scholar
• Dostal M, Weber‐Schoendorfer C, Sobesky J, et al. Pregnancy outcome following use of levodopa, pramipexole, ropinirole, and rotigotine for restless legs syndrome during pregnancy: a case series. Eur J Neurol. 2013;20:1241–1246.
   PubMed Web of Science ®Google Scholar
• Picchietti D, Allen RP, Walters AS, et al. Restless legs syndrome: prevalence and impact in children and adolescents—the Peds REST study. Pediatrics. 2007;120:253–266.
   PubMed Web of Science ®Google Scholar
• Turkdogan D, Bekiroglu N, Zaimoglu S. A prevalence study of restless legs syndrome in Turkish children and adolescents. Sleep Med. 2011;12:315–321.
   PubMed Web of Science ®Google Scholar
• Picchietti DL, Bruni O, De Weerd A, et al. Pediatric restless legs syndrome diagnostic criteria: an update by the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14:1253–1259.
   PubMed Web of Science ®Google Scholar
• Amos LB, Grekowicz ML, Kuhn EM, et al. Treatment of pediatric restless legs syndrome. Linical Pediatr (Phila). 2014;53:331–336.
   PubMed Web of Science ®Google Scholar
• Tilma J, Tilma K, Norregaard O, et al. Early childhood‐onset restless legs syndrome: symptoms and effect of oral iron treatment. Acta Pædiatr. 2013;102:e221–e226.
   PubMed Web of Science ®Google Scholar
• Dye TJ, Jain SV, Simakajornboon N. Outcomes of long-term iron supplementation in pediatric restless legs syndrome/periodic limb movement disorder (RLS/PLMD). Sleep Med. 2017;32:213–219.
   PubMed Web of Science ®Google Scholar
• Tippmann-Peikert M, Park JG, Boeve BF, et al. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology. 2007;68:301–303.
   PubMed Web of Science ®Google Scholar
• Dang D, Cunnington D, Swieca J. The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome. Clin Neuropharmacol. 2011;34:66–70.
   PubMed Web of Science ®Google Scholar
• Heim B, Djamshidian A, Heidbreder A, et al. Augmentation and impulsive behaviors in restless legs syndrome Coexistence or association? Neurology. 2016;87:36–40.
   PubMed Web of Science ®Google Scholar
• Giannaki CD, Sakkas GK, Karatzaferi C, et al. Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study. BMC Nephrol. 2013;14:194.
   PubMed Web of Science ®Google Scholar